Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review.

Georgiou, Petros; Shi, Wangpan; Serhiyenia, Tatsiana; Akram, Aqsa; Proute, Matthew C; Pradeep, Roshini; Kerolos, Mina E; Khan, Safeera

Georgiou, Petros; Shi, Wangpan; Serhiyenia, Tatsiana; Akram, Aqsa; Proute, Matthew C; Pradeep, Roshini; Kerolos, Mina E; Khan, Safeera.

Afiliación

Georgiou P; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Shi W; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Serhiyenia T; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Akram A; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Proute MC; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Pradeep R; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Kerolos ME; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Khan S; Department of Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Cureus ; 13(10): e18485, 2021 Oct.

Article en En | MEDLINE | ID: mdl-34754647

Palabras clave

cardiovascular benefit; cardiovascular disease; cardiovascular outcome trials; diabetes type 2; sodium-glucose cotransporter 2 inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Cureus Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google